您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2016, Vol. 54 ›› Issue (8): 1-5.doi: 10.6040/j.issn.1671-7554.0.2015.1336

• •    下一篇

血管紧张素Ⅳ型受体过表达对早期动脉粥样硬化斑块形成的影响

魏丹丹,张澄   

  1. 山东大学齐鲁医院教育部和卫生部心血管重构与功能研究重点实验室, 山东 济南 250012
  • 收稿日期:2015-12-24 出版日期:2016-08-10 发布日期:2016-08-10
  • 通讯作者: 张澄. E-mail:zhangc@sdu.edu.cn E-mail:zhangc@sdu.edu.cn
  • 基金资助:
    国家自然科学基金(91339109)

Effects of the overexpression of type 4 angiotensin receptor on the formation of atherosclerotic lesions

WEI Dandan, ZHANG Cheng   

  1. Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China
  • Received:2015-12-24 Online:2016-08-10 Published:2016-08-10

PDF (PC)

277

摘要： 目的 探讨血管紧张素Ⅳ型受体(AT4R)过表达对早期动脉粥样硬化斑块形成的影响及可能机制。 方法 ApoE-/-小鼠60只高脂饮食喂养4周后,随机分为AT4R过表达组(Ad-AT4R组)、空载体组(Ad-EGFP组)和PBS空白对照组,每组20只。分别通过尾静脉注射携带有AT4R的腺病毒、腺病毒空载体及PBS溶液。继续高脂饮食4周后处死小鼠,留取血样及血管组织。检测血糖及血脂各项指标;采用苏木精-伊红染色法及油红O染色检测主动脉根部斑块面积百分比。 结果 与空白对照组和Ad-EGFP组相比,Ad-AT4R组体质量、血糖及血脂无显著性差异(P>0.05),苏木精-伊红染色及油红O染色斑块面积百分比显著降低(P<0.05)。 结论 AT4R过表达可抑制早期动脉粥样硬化斑块的形成,且不依赖于对血糖、血脂水平的调节。因此,AT4R可能存在潜在抗动脉粥样硬化的作用。

关键词: 动脉粥样硬化, 早期斑块形成, 血管紧张素Ⅳ型受体

Abstract: Objective To explore the effects of type 4 angiotensin receptor(AT4R)on the formation of atherosclerotic lesions and to elaborate the possible mechanism. Methods A total of 60 apolipoprotein E-deficient mice fed with high-fat diet for 4 weeks were randomly divided into 3 groups: control group(receiving infusion of PBS), Ad-EGFP group(receiving infusion of adenoviral vectors with green fluorescence protein)and Ad-AT4R group(receiving infusion of adenoviral vectors with AT4R). High-fat diet lasted for another 4 weeks and then all mice were sacrificed to collect blood samples and whole aorta. The levels of blood glucose and blood lipid were measured. The aortic plaques were stained by HE and oil red O staining method to measure the percentage of positive atherosclerotic lesion area. Results There was no significant difference in blood glucose and serum lipid levels among the 3 groups. However, compared to the control group and the Ad-EGFP group, the Ad-AT4R group showed lower positive atherosclerotic lesion area stained by HE and oil red(P<0.05). Conclusion Overexpression of AT4R may inhibit the formation of atherosclerotic lesions independent of regulation of blood glucose and serum lipid. Thus AT4R may provide protection against atherosclerosis.

Key words: Type 4 angiotensin receptor, Atherosclerosis, Formation of atherosclerotic lesions

中图分类号: 

  • R543.1
[1] Ruiz-Ortega M, Lorenzo O, Ruperez M, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field[J]. Hypertension, 2001, 38(6): 1382-1387.
[2] Chai SY, Fernando R, Peck G, et al. The angiotensin Ⅳ/AT4 receptor[J]. Cell Mol Life Sci, 2004, 61(21): 2728-2737.
[3] Vanderheyden PM. From angiotensin Ⅳ binding site to AT4 receptor[J]. Mol Cell Endocrinol, 2009, 302(2): 159-166.
[4] Albiston AL, McDowall SG, Matsacos D, et al. Evidence that the angiotensin Ⅳ(AT(4))receptor is the enzyme insulin-regulated aminopeptidase[J]. J Biol Chem, 2001, 276(52): 48623-48626.
[5] Thomas WG, Mendelsohn FA. Angiotensin receptors: form and function and distribution[J]. Int J Biochem Cell Biol, 2003, 35(6): 774-779.
[6] Wright JW, Krebs LT, Stobb JW, et al. The angiotensin Ⅳ system: functional implications[J]. Front Neuroendocrinol, 1995, 16(1): 23-52.
[7] Patel JM, Martens JR, Li YD, et al. Angiotensin Ⅳ receptor-mediated activation of lung endothelial NOS is associatied with vasorelaxation[J]. 1998, 275(6 Pt 1): 1061-1068.
[8] Chen S, Patel JM, Block ER. Angiotensin Ⅳ-mediated pulmonary artery vasorelaxation is due to endothelial intracellular calcium release[J]. Am J Physiol Lung Cell Mol Physiol, 2000, 279(5): 849-856.
[9] Moeller I, Clune EF, Fennessy PA, et al. Up regulation of AT4 receptor levels in carotid arteries following balloon injury[J]. Regul Pept, 1999, 83(1): 25-30.
[10] Numaguchi Y, Ishii M, Kubota R, et al. Ablation of angiotensin Ⅳ receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis[J]. Arterioscler Thromb Vasc Biol, 2009, 29(12): 2102-2108.
[11] Yang H, Zeng XJ, Wang HX, et al. Angiotensin Ⅳ protects against angiotensin Ⅱ-induced cardiac injury via AT4 receptor[J]. Peptides, 2011, 32(10): 2108-2115.
[12] Vinh A, Widdop RE, Drummond GR, et al. Chronic angiotensin Ⅳ treatment reverses endothelial dysfunction in ApoE-deficient mice[J]. Cardiovasc Res, 2008, 77(1): 178-187.
[13] Vinh A, Widdop RE, Chai SY, et al. Angiotensin Ⅳ-evoked vasoprotection is conserved in advanced atheroma[J]. Atherosclerosis, 2008, 200(1): 37-44.
[14] 蒲丽君, 黄颂敏. 血管紧张素Ⅳ/AT4受体系统研究进展[J]. 国际泌尿系统杂志, 2006, 26(2): 283-286.
[15] Faure S, Chapot R, Tallet D, et al. Cerebroprotective effect of angiotensin Ⅳ in experimental ischemic stroke in the rat mediated by AT(4)receptors[J]. J Physiol Pharmacol, 2006, 57(3): 329-342.
[16] Hall KL, Venkateswaran S, Hanesworth JM, et al. Characterization of a functional angiotensin Ⅳ receptor on coronary microvascular endothelial cells[J]. Regul Pept, 1995, 58(3): 107-115.
[17] Davis CJ, Kramar EA, De A, et al. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation[J]. Neuroscience, 2006, 137(4): 1369-1379.
[18] Lee J, Mustafa T, McDowall SG, et al. Structure-activity study of LVV-hemorphin-7: angiotensin AT4 receptor ligand and inhibitor of insulin-regulated aminopeptidase[J]. J Pharmacol Exp Ther, 2003, 305(1): 205-211.
[19] Lew RA, Mustafa T, Ye S, et al. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase(IRAP)[J]. J Neurochem, 2003, 86(2): 344-350.
[20] Handa RK, Harding JW, Simasko SM. Characterization and function of the bovine kidney epithelial angiotensin receptor subtype 4 using angiotensin Ⅳ and divalinal angiotensin Ⅳ as receptor ligands[J]. J Pharmacol Exp Ther, 1999, 291(3): 1242-1249.
[1] 付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24-31.
[2] 尹妮,杨关林,姜钧文,王春田,王凤耀,贾连群,高晓宇,潘嘉祥,李芹,李佳,冯元洁,高玉竹,周鹤,张哲. 巴马小型猪冠状动脉粥样硬化模型的评价方法[J]. 山东大学学报（医学版）, 2017, 55(7): 1-5.
[3] 张云华,李杰. 颈动脉斑块内新生血管显影程度及血浆Lp-PLA2水平对急性脑梗死的临床诊断价值[J]. 山东大学学报（医学版）, 2017, 55(3): 112-116.
[4] 王丹,亓恒涛,孙书珍. 原发性肾病综合征儿童颈动脉结构和功能改变[J]. 山东大学学报（医学版）, 2016, 54(5): 88-91.
[5] 孙鹏飞,孟晓,张凯,黎莉. 抵抗素样分子 β在动脉粥样硬化斑块稳定性中的作用[J]. 山东大学学报（医学版）, 2016, 54(3): 1-4.
[6] 李雪丽,徐丽君. 以孤立性眩晕为首发症状的双侧对称性桥臂梗死1例[J]. 山东大学学报（医学版）, 2016, 54(12): 90-92.
[7] 王小飞, 王成伟, 王志刚, 丁璇, 王敏卿. 应用Enterprise支架治疗动脉粥样硬化性椎-基底动脉狭窄的探讨[J]. 山东大学学报（医学版）, 2015, 53(8): 44-48.
[8] 于昕, 刘晓静, 刘向群. 黄芩苷抑制ox-LDL诱导内皮细胞凋亡的作用[J]. 山东大学学报（医学版）, 2015, 53(5): 5-9.
[9] 谭蓓, 关玉庆, 孙慧, 户克庆, 苏国海, 韦敏. 血管内超声检测阿托伐他汀对兔动脉粥样硬化斑块的影响[J]. 山东大学学报（医学版）, 2015, 53(5): 10-14.
[10] 段瑞生. 他汀对动脉粥样硬化的免疫调节及其在临床应用中的思考[J]. 山东大学学报（医学版）, 2015, 53(5): 1-4.
[11] 于磊, 李振. 白细胞介素33在脑血管病患者血清中的表达及其作用机制[J]. 山东大学学报（医学版）, 2015, 53(4): 75-79.
[12] 徐忠阳, 王立启, 徐振兴, 赵乾, 朱世明. RhoA/ROCK信号通路与原发性高血压患者血压变异性及颈动脉内膜中层厚度的相关性[J]. 山东大学学报（医学版）, 2015, 53(2): 48-51.
[13] 刘国明, 史浩, 程海超. DCE-MRI在颈动脉粥样硬化斑块新生血管定量测量中的应用[J]. 山东大学学报（医学版）, 2015, 53(12): 76-80.
[14] 容春莉, 姚文静, 杨倩, 李如意, 曹东平, 刘美霞, 彭应心. 阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症的临床疗效[J]. 山东大学学报（医学版）, 2015, 53(11): 46-49.
[15] 靳成伟, 李葵, 赵静, 岳欣, 尚嫄嫄, 韩露, 张运, 张薇, 马骁, 钟明. 外周血单核细胞甘油三酯水解酶的表达与代谢综合征的相关性[J]. 山东大学学报（医学版）, 2014, 52(8): 39-42.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发